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Background: Tacrolimus has become a mainstay in the
prevention and treatment of graft versus host disease
(GVHD) in allogeneic hematopoietic stem cell transplant
(allo-HSCT). Tacrolimus has high potential for toxicity and
requires therapeutic drug monitoring due to its narrow
therapeutic drug index, with noted inter-subject variability.
The hepatic cytochrome P450 pathway metabolizes the
immunosuppressant, with recent studies revealing the
inﬂuence of selected single-nucleotide polymorphisms
(SNPs) in CYP3A4 and CYP3A5 genotypes that may inﬂuence
tacrolimus pharmacokinetics (PK) and outcomes. To our
knowledge, the inﬂuence of CYP3A4 and CYP3A5 genotypes
on tacrolimus pharmacokinetics and pharmacodynamics
(PD) has not been thoroughly studied in allo-HSCT
population.
Objectives: The primary objectives of the study are to 1)
determine the effects of CYP3A4*22 and CYP3A5*1
genotypes on the pharmacokinetics of tacrolimus in
allo-HSCT patients; 2) develop a comprehensive model
for optimal tacrolimus starting doses in patients
receiving allogeneic HSCT and monitoring for continued
therapy.
Study Design: A prospective, double-blinded cohort study is
currently accruing patients in the adult allo-HSCT setting at
The Ohio State University Comprehensive Cancer Center.
Inclusion criteria: First time allo-HSCT from related or
unrelated donors matched for 10/10 or 9/10 human leuko-
cyte antigen (HLA)-A, -B, -C, -DRB1, and - DQB1 alleles
receiving tacrolimus, > 18 years of age, and no prior tacro-
limus exposure. The status of CYP3A4*22, CYP3A5*1 and
CYP3A5*3 genotypes is determined prior to transplant. Serial
blood samples are collected to characterize the PK for ﬁrst
and steady state tacrolimus doses. A validated liquid chro-
matography-mass spectrometry (LC/MS) assay is used to
measure tacrolimus and selected metabolites level. The
study is approved by the Institutional Review Board (IRB)
and enrollment began in June 2012.
Results: The study has accrued 33 subjects to date. Prelimi-
nary pharmacogenetic-pharmacokinetic interim data as well
as parent drug and CP3A4/5-mediatedmetabolites PK will be
presented.
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The treatment of choice for proven or probable fungal infection
prior to haematopoetic stem cell transplant (HSCT) is often
a mould active azole. The decision to continue these agents
through the transplant period has resulted in debate in
managing drug interactions and dosing of cyclosporin (CSA) as
hepatic microenzyme inhibition predicts decreasedmetabolism
and subsequent clearance of CSA. In 2008 following a number of
supratherapeutic levels inpatients treatedwithvoriconazoleand
standarddoseCSAour center reducedup front CSAdoses by 40%
for patients receiving voriconazole prior to and during HSCT.
Aim: To determine if upfront CSA dose reduction when used
in combination with voriconazole resulted in similar graft
versus host disease (GVHD) incidence compared to patients
treated with no mould active azole and standard dose CSA.
Method: An analysis of allogeneic HCST activity performed
between mid 2008 and 2012 identiﬁed 78 pediatric
patients undergoing HSCT for malignant disease and
immunodeﬁciencies.
The patients were grouped according to fungal prophy-
laxis and starting CSA dose. Patients without previous fungal
infection received IV CSA 5mg/kg/day with ﬂuconazole or
liposomal amphotericin. Patients with previous fungal
infection who received voriconazole prior to HSCT were
prescribed a 40% reduced dose of CSA at 3mg/kg/day. To
account for drug interactions with the preparative regimen
patients received liposomal amphotericin from the start of
conditioning and re-commenced voriconazole on day 0.
CSA levels were evaluated from Day 0 to 8. The incidence
of grade II-IV GVHD was compared in the two groups.
Results: The groups were equal for donor source, remission
status and mean day to engraftment (17.6 vs 18). 61 patients
(78.3%) received full dose CSA with no mould active azole
and 17 (21.7%) patients received voriconazole and an initial
40% dose reduction in CSA.
Day 0 CSA levels in the reduced dose were lower (71.3 vs
134.3 P ¼ .04) however by day 8 there was no difference in the
mean CSA levels. CSA doses were adjusted according to levels
and there were equal numbers of dose adjustments in both
groups. Despite early low CSA levels, there was no difference in
the incidence of grade II-IV GVHD, 47.05% in patients receiving
upfront dose reduction and 41% in full dose (P ¼ .358).
It was difﬁcult to assess toxicity as patients may have also
received voriconazole later in the transplant course. There
were similar rates of acute kidney injury however GGT was
elevated in patients who received voriconazole at any time
point. There were no other distinguishing toxicity features
between the groups.
Conclusion: An initial 40% dose reduction of CSA for patients
receiving voriconazole results in lower initial CSA levels but
does not translate into an increased incidence of grade II-IV
GVHD. Future transplant patients requiring voriconazole
prophylaxis should receive initial dose reduction in CSA.
